Open Access Short Communication Article ID: APRC-6-163

    Latent Multi-drug Resistant Tuberculosis: An Unaddressed Problem

    Gyanshankar Mishra* and Jasmin Mulani

    It is estimated that three of every 1,000 individuals worldwide have latent Multidrug-Resistant Tuberculosis (MDR-TB) infection. Management of latent MDR-TB is an integral component in our strategies targeting global TB elimination. We are currently targeting only latent drug-sensitive TB as there are no consensus guidelines on the management of latent MDR-TB. Such an approach can potentially lead to a “fall and rise phenomenon” in latent MDR-TB. Risk factors for latent MDR-TB need to be identified, and high-risk individuals need to be screened and treated on priority for latent MDR-TB. The treatment of latent MDR-TB can be initiated primarily with fluoroquinolones-based treatment regimes. Such regimes need to be individualized based on the drug sensitivity pattern of the source case isolate of drug-resistant TB. Thus, strategies for managing latent MDR-TB are the need of the day.


    Published on: Nov 25, 2020 Pages: 84-86

    Full Text PDF Full Text HTML DOI: 10.17352/aprc.000063
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat


    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on APRC

    Google Reviews 11